Literature DB >> 23504480

The efficacy of cardiac findings in assessing the outcome in preterms with bronchopulmonary dysplasia.

Abdullah Barış Akcan1, Fırat Kardelen, Seyhan Erişir Oygucu, Abdullah Kocabaş, Deniz Ozel, Halide Akbaş, Nihal Oygür.   

Abstract

OBJECTIVES: To evaluate if cardiac dysfunctions are important in assessing the outcome in newborns with Bronchopulmonary Dysplasia (BPD), by evaluating cardiac functions with N-terminal prohormone of brain natriüretic peptide (NT-proBNP) levels, M-mode and tissue doppler echocardiography at 6-12 mo of age.
METHODS: Twenty eight patients were retrospectively classified as mild, moderate and severe according to the diagnostic criterias for BPD. All cases were assessed with standard M-mode, tissue doppler echocardiography and NT-proBNP levels. Control group consisted of 28 healthy infants, having similar postnatal ages as patients and were assessed with standard M-mode and tissue doppler echocardiography.
RESULTS: The age of patients with BPD was 9.8 ± 2.3 mo and control group was 9.5 ± 2.6 mo. There was no significant difference between the postnatal ages of two groups (p > 0.05). Neither pulmonary hypertension nor pulmonary/tricuspid regurgitation was detected. The M-mode echocardiography measurements did not differ between patients and control group (p > 0.05). Tissue doppler echocardiography, tricuspid valve medial segment early diastolic myocardial relaxation velocity (TME') measurements of patients were found significantly lower, peak transtricuspid filling velocity in the early diastole (TE)/TME' ratios and isovolumetric relaxation time (IVRT) measurements were found significantly higher than control group (p < 0.05). Tricuspid E, TE/TLE' (Tricuspid valve lateral segment early diastolic myocardial relaxation velocity), TE/RVLE'(Right ventricular lateral segment early diastolic myocardial relaxation velocity), TE/TME' levels were also found as significantly abnormal in patients with severe BPD. A significant correlation was found between right ventricular diastolic disfunctions and severity of BPD (p < 0.05). No statistically significant difference was found between NT-proBNP levels, BPD stages and tissue doppler echocardiography measurements (p > 0.05).
CONCLUSIONS: This is the first study evaluating cardiac findings in patients with BPD by tissue doppler echocardiography and NT-proBNP at the same time. On the basis of cardiac evaluations, tissue doppler echocardiography measurements were found as significant and specific for the early assessment of right ventricular diastolic disfunctions.

Entities:  

Mesh:

Year:  2013        PMID: 23504480     DOI: 10.1007/s12098-013-0994-y

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  29 in total

1.  Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia.

Authors:  W H Northway; R C Rosan; D Y Porter
Journal:  N Engl J Med       Date:  1967-02-16       Impact factor: 91.245

2.  Thoracic duct lymph flow in fetal sheep with increased venous pressure from electrically induced tachycardia.

Authors:  A L Gest; D K Bair; M C Vander Straten
Journal:  Biol Neonate       Date:  1993

3.  Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn.

Authors:  Eric W Reynolds; Jeff G Ellington; Mark Vranicar; Henrietta S Bada
Journal:  Pediatrics       Date:  2004-11       Impact factor: 7.124

4.  N-terminal pro-B-type natriuretic peptide as a marker of bronchopulmonary dysplasia in premature infants.

Authors:  Leon Joseph; Amiram Nir; Cathy Hammerman; Shmuel Goldberg; Efrat Ben Shalom; Elie Picard
Journal:  Am J Perinatol       Date:  2009-12-11       Impact factor: 1.862

5.  Cardiopulmonary function in premature infants with bronchopulmonary dysplasia--a 2-year follow up.

Authors:  T Farstad; F Brockmeier; D Bratlid
Journal:  Eur J Pediatr       Date:  1995-10       Impact factor: 3.183

6.  Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants.

Authors:  V F Puddy; C Amirmansour; A F Williams; D R J Singer
Journal:  Clin Sci (Lond)       Date:  2002-07       Impact factor: 6.124

7.  N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases.

Authors:  A Nir; B Bar-Oz; Z Perles; R Brooks; A Korach; A J J T Rein
Journal:  Acta Paediatr       Date:  2004-05       Impact factor: 2.299

Review 8.  NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies.

Authors:  Amiram Nir; Angelika Lindinger; Manfred Rauh; Benjamin Bar-Oz; Stephanie Laer; Lynn Schwachtgen; Andreas Koch; Jan Falkenberg; Thomas S Mir
Journal:  Pediatr Cardiol       Date:  2008-07-04       Impact factor: 1.655

9.  The effect of outflow pressure upon thoracic duct lymph flow rate in fetal sheep.

Authors:  A L Gest; D K Bair; M C Vander Straten
Journal:  Pediatr Res       Date:  1992-11       Impact factor: 3.756

10.  Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth.

Authors:  M Yoshibayashi; T Kamiya; Y Saito; K Nakao; K Nishioka; S Temma; H Itoh; G Shirakami; H Matsuo
Journal:  Eur J Endocrinol       Date:  1995-08       Impact factor: 6.664

View more
  2 in total

1.  Myocardial Function Maturation in Very-Low-Birth-Weight Infants and Development of Bronchopulmonary Dysplasia.

Authors:  Paula Méndez-Abad; Pamela Zafra-Rodríguez; Simón Lubián-López; Isabel Benavente-Fernández
Journal:  Front Pediatr       Date:  2020-01-17       Impact factor: 3.418

Review 2.  Serum and Urinary N-Terminal Pro-brain Natriuretic Peptides as Biomarkers for Bronchopulmonary Dysplasia of Preterm Neonates.

Authors:  Zoi Iliodromiti; Evangelos Christou; Nikolaos Vrachnis; Rozeta Sokou; Dionysios Vrachnis; Georgia Mihopoulou; Theodora Boutsikou; Nicoletta Iacovidou
Journal:  Front Pediatr       Date:  2020-10-28       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.